RT Journal Article
T1 Intravenous iron in inflammatory bowel disease
A1 Muñoz, Manuel
A1 Gómez-Ramírez, Susana
A1 García-Erce, José Antonio
K1 Ferric oxide, saccharated
K1 Anemia
K1 Iron deficiency
K1 Functional iron deficiency
K1 Erythropoiesis stimulating agents
K1 Oral Iron
K1 Intravenous Iron
K1 Gluconatos
K1 Enfermedades Inflamatorias del Intestino
K1 Infusiones Intravenosas
K1 Inyecciones Intraventriculares
K1 Hierro
K1 Complejo Hierro-Dextran
K1 Maltosa
K1 Compuestos Férricos
K1 Resultado del Tratamiento
AB The prevalence of anemia across studies on patients with inflammatory bowel disease (IBD) is high (30%). Both iron deficiency (ID) and anemia of chronic disease contribute most to the development of anemia in IBD. The prevalence of ID is even higher (45%). Anemia and ID negatively impact the patient's quality of life. Therefore, together with an adequate control of disease activity, iron replacement therapy should start as soon as anemia or ID is detected to attain a normal hemoglobin (Hb) and iron status. Many patients will respond to oral iron, but compliance may be poor, whereas intravenous (i.v.) compounds are safe, provide a faster Hb increase and iron store repletion, and presents a lower rate of treatment discontinuation. Absolute indications for i.v. iron treatment should include severe anemia, intolerance or inappropriate response to oral iron, severe intestinal disease activity, or use of an erythropoietic stimulating agent. Four different products are principally used in clinical practice, which differ in their pharmacokinetic properties and safety profiles: iron gluconate and iron sucrose (lower single doses), and iron dextran and ferric carboxymaltose (higher single doses). After the initial resolution of anemia and the repletion of iron stores, the patient's hematological and iron parameters should be carefully and periodically monitored, and maintenance iron treatment should be provided as required. New i.v. preparations that allow for giving 1000-1500 mg in a single session, thus facilitating patient management, provide an excellent tool to prevent or treat anemia and ID in this patient population, which in turn avoids allogeneic blood transfusion and improves their quality of life.
PB Baishideng Publishing Group Co. Limited
SN 1007-9327
YR 2009
FD 2009-10-07
LK http://hdl.handle.net/10668/723
UL http://hdl.handle.net/10668/723
LA en
NO Muñoz M, Gómez-Ramírez S, García-Erce JA. Intravenous iron in inflammatory bowel disease. World J. Gastroenterol. 2009; 15(37):4666-74
NO Journal Article; Review;
DS RISalud
RD Apr 17, 2025